MedScout raises $10M growth round, rolls out “Strategies” AI agents for MedTech sales teams
Fulcrum Equity Partners led the financing, with Live Oak Venture Partners and Stage 2 Capital participating; the company says it has tripled enterprise revenue since its July 2024 Series A.
MedScout closed a $10 million growth funding round led by Fulcrum Equity Partners, with participation from existing investors Live Oak Venture Partners and Stage 2 Capital. The Austin-based company’s round more than doubled its valuation compared with its prior Series A and will be used to continue investing in its AI product capabilities and to support demand from enterprise customers.
Alongside the funding, MedScout announced the launch of “Strategies,” a set of AI agents designed to translate commercial strategy into territory-level plans for field representatives. The company said the agents analyze inputs such as market and account-level referral networks, procedure volumes, and payer dynamics to generate prioritized target lists and recommended actions.
MedScout framed the product around a common operational gap in MedTech sales: strategy is set centrally, while field teams often rely on a mix of search, spreadsheets, and data tools that do not provide guidance on what to do next. The company said each agent is configured to a customer’s commercial approach and definition of target accounts, and that Strategies became available to customers in late 2025.
The company also shared adoption and growth metrics it attributed to customer activity: MedScout said customers deployed 81% more unique AI agents in January than in the prior month, and that enterprise revenue has grown 3x since its July 2024 Series A. It also reported 135% month-over-month growth in monthly active reps as customers expanded usage.
